Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Working Capital Changes (2018 - 2025)

Historic Other Working Capital Changes for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to -$2.7 million.

  • 10x Genomics' Other Working Capital Changes rose 3.68% to -$2.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$10.3 million, marking a year-over-year increase of 1741.43%. This contributed to the annual value of -$10.3 million for FY2025, which is 1741.43% up from last year.
  • Latest data reveals that 10x Genomics reported Other Working Capital Changes of -$2.7 million as of Q4 2025, which was up 3.68% from -$2.6 million recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' Other Working Capital Changes ranged from a high of $10.5 million in Q1 2023 and a low of -$15.6 million during Q3 2024
  • Its 5-year average for Other Working Capital Changes is -$1.1 million, with a median of -$1.3 million in 2021.
  • In the last 5 years, 10x Genomics' Other Working Capital Changes plummeted by 444824.56% in 2022 and then skyrocketed by 41545.76% in 2023.
  • Quarter analysis of 5 years shows 10x Genomics' Other Working Capital Changes stood at -$620000.0 in 2021, then tumbled by 199.52% to -$1.9 million in 2022, then soared by 331.29% to $4.3 million in 2023, then plummeted by 163.35% to -$2.7 million in 2024, then increased by 0.04% to -$2.7 million in 2025.
  • Its Other Working Capital Changes stands at -$2.7 million for Q4 2025, versus -$2.6 million for Q3 2025 and -$10.5 million for Q2 2025.